What to expect from a third step in treatment resistant depression: A prospective open study on escitalopram

References

• Adli, M., C. Baethge, A. Heinz, N. Langlitz and M. Bauer (2005). ”Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255(6): 387–400.
   Google Scholar
• Ali, M. K. and R. W. Lam (2011). Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 7: 39–49.
   PubMed Web of Science ®Google Scholar
• Bauer, M., P. Tharmanathan, H. P. Volz, H. J. Moeller and N. Freemantle (2009). The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 259(3): 172–185.
   PubMed Web of Science ®Google Scholar
• Berlim, M. T. and G. Turecki (2007). ”What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol 17(11): 696–707.
   Google Scholar
• Bielski, R. J., D. Ventura and C. C. Chang (2004). A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 65(9): 1190–1196.
   PubMed Web of Science ®Google Scholar
• Bose, A., J. Tsai and D. Li (2012). Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clin Drug Investig 32(6): 373–385.
   PubMed Web of Science ®Google Scholar
• Bschor, T. and C. Baethge (2010). No evidence for switching the antidepressant: systematic review and meta-analysis of RCTs of a common therapeutic strategy. Acta Psychiatr Scand 121(3): 174–179.
   PubMed Web of Science ®Google Scholar
• Burke, W. J., I. Gergel and A. Bose (2002). Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 63(4): 331–336.
   PubMed Web of Science ®Google Scholar
• Chen, Y. M., X. M. Huang, R. Thompson and Y. B. Zhao (2011). Clinical features and efficacy of escitalopram treatment for geriatric depression. J Int Med Res 39(5): 1946–1953.
   PubMed Web of Science ®Google Scholar
• CHMP (2002). Note for guidance on clinical investigation of medicinal products in the treatment of depression. http://www.emea.europa.eu/pdfs/human/ewp/051897en.pdf.
   Google Scholar
• Cipriani, A., T. A. Furukawa, G. Salanti, J. R. Geddes, J. P. Higgins, R. Churchill, et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 373(9665): 746–758.
   PubMed Web of Science ®Google Scholar
• Cipriani, A., C. Santilli, T. A. Furukawa, A. Signoretti, A. Nakagawa, H. McGuire, et al. (2009). Escitalopram versus other antidepressive agents for depression.” Cochrane Database Syst Rev(2): CD006532.
   Google Scholar
• Committee for Medicinal Products for Human Use (2002). Note for guidance on clinical investigation of medicinal products in the treatment of depression. http://www.emea.europa.eu/pdfs/human/ewp/051897en.pdf.
   Google Scholar
• Committee for Medicinal Products for Human Use. (2013). Guideline on clinical investigation of medicinal products in the treatment of depression. Retrieved 30/09/2014, 2014, from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/05/WC500143770.pdf.
   Google Scholar
• Corya, S. A., D. Williamson, T. M. Sanger, S. D. Briggs, M. Case and G. Tollefson (2006). A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety 23(6): 364–372.
   PubMed Web of Science ®Google Scholar
• de Montigny, C., P. H. Silverstone, G. Debonnel, P. Blier and D. Bakish (1999). Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol 19(5): 401–406.
   PubMed Web of Science ®Google Scholar
• Fang, Y., C. Yuan, Y. Xu, J. Chen, Z. Wu, L. Cao, et al. (2010). Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. J Clin Psychopharmacol 30(4): 357–364.
   PubMed Web of Science ®Google Scholar
• Fava, M. (2003). Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 53(8): 649–659.
   PubMed Web of Science ®Google Scholar
• Gaynes, B. N., S. B. Dusetzina, A. R. Ellis, R. A. Hansen, J. F. Farley, W. C. Miller, et al. (2012). Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D. J Clin Psychopharmacol 32(1): 114–119.
   PubMed Web of Science ®Google Scholar
• Guy, W. (1976). ECDEU Assessment manual for psychopharmacology: revised. Rockville, MD.
   Google Scholar
• Hamilton, M. (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
   PubMed Web of Science ®Google Scholar
• Kasper, S., D. S. Baldwin, S. Larsson Lonn and J. P. Boulenger (2009). Superiority of escitalopram to paroxetine in the treatment of depression. Eur Neuropsychopharmacol 19(4): 229–237.
   PubMed Web of Science ®Google Scholar
• Kasper, S., J. Sacher, N. Klein, N. Mossaheb, T. Attarbaschi-Steiner, R. Lanzenberger, et al. (2009). Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 24(3): 119–125.
   PubMed Web of Science ®Google Scholar
• Kennedy, S. H., H. F. Andersen and M. E. Thase (2009). Escitalopram in the treatment of major depressive disorder: a meta-analysis. Curr Med Res Opin 25(1): 161–175.
   PubMed Web of Science ®Google Scholar
• Kilts, C. D., A. G. Wade, H. F. Andersen and T. E. Schlaepfer (2009). Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother 10(6): 927–936.
   PubMed Web of Science ®Google Scholar
• Kirino, E. (2012). Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 6: 853–861.
   PubMed Web of Science ®Google Scholar
• Kornstein, S. G., D. Li, Y. Mao, S. Larsson, H. F. Andersen and G. I. Papakostas (2009). Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials. CNS Spectr 14(6): 326–333.
   PubMed Web of Science ®Google Scholar
• Lam, R. W., S. L. Lonn and N. Despiegel (2010). Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. Int Clin Psychopharmacol 25(4): 199–203.
   PubMed Web of Science ®Google Scholar
• Laux, G., M. Friede and W. E. Muller (2013). Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study. Pharmacopsychiatry 46(1): 16–22.
   PubMed Web of Science ®Google Scholar
• Leonard, B. and D. Taylor (2010). Escitalopram translating molecular properties into clinical benefit: reviewing the evidence in major depression. J Psychopharmacol 24(8): 1143–1152.
   PubMed Web of Science ®Google Scholar
• Licht, R. W. and S. Qvitzau (2002). ”Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation. Psychopharmacology (Berl) 161(2): 143–151.
   PubMed Web of Science ®Google Scholar
• Lingjaerde, O., U. G. Ahlfors, P. Bech, S. J. Dencker and K. Elgen (1987). ”The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334: 1–100.
   PubMedGoogle Scholar
• Mbaya, P. (2002). Safety and efficacy of high dose of venlafaxine XL in treatment resistant major depression. Hum Psychopharmacol 17(7): 335–339.
   PubMed Web of Science ®Google Scholar
• Montgomery, S. and M. Asberg (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134: 382–389.
   PubMed Web of Science ®Google Scholar
• Montgomery, S., T. Hansen and S. Kasper (2011). Efficacy of escitalopram compared to citalopram: a meta-analysis. Int J Neuropsychopharmacol 14(2): 261–268.
   PubMed Web of Science ®Google Scholar
• Montgomery, S. A. and H. F. Andersen (2006). Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 21(5): 297–309.
   PubMed Web of Science ®Google Scholar
• Power, R. A., B. Muthen, N. Henigsberg, O. Mors, A. Placentino, J. Mendlewicz, et al. (2012). Non-random dropout and the relative efficacy of escitalopram and nortriptyline in treating major depressive disorder. J Psychiatr Res 46(10): 1333–1338.
   PubMed Web of Science ®Google Scholar
• Rapaport, M. H., G. M. Gharabawi, C. M. Canuso, R. A. Mahmoud, M. B. Keller, C. A. Bossie, et al. (2006). Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31(11): 2505–2513.
   PubMed Web of Science ®Google Scholar
• Ruhe, H. G., J. Huyser, J. A. Swinkels and A. H. Schene (2006). Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review. J Clin Psychiatry 67(12): 1836–1855.
   PubMed Web of Science ®Google Scholar
• Rush, A. J., M. H. Trivedi, S. R. Wisniewski, J. W. Stewart, A. A. Nierenberg, M. E. Thase, et al. (2006). Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354(12): 1231–1242.
   PubMed Web of Science ®Google Scholar
• Saiz-Ruiz, J., A. Ibanez, M. Diaz-Marsa, F. Arias, J. Padin, M. Martin-Carrasco, et al. (2002). Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 26(6): 1129–1134.
   PubMed Web of Science ®Google Scholar
• Sanchez, C., E. H. Reines and S. A. Montgomery (2014). A comparative review of escitalopram, paroxetine, and sertraline: are they all alike? Int Clin Psychopharmacol 29(4): 185–196.
   PubMed Web of Science ®Google Scholar
• Schweitzer, I., G. Burrows, V. Tuckwell, A. Polonowita, P. Flynn, T. George, et al. (2001). Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol 21(2): 185–189.
   PubMed Web of Science ®Google Scholar
• Sheehan, D. V. (1983). The Anxiety Disease. New York, Charles Scribner & Sons.
   Google Scholar
• Signorovitch, J., K. Ramakrishnan, R. Ben-Hamadi, A. P. Yu, E. Q. Wu, H. Dworak, et al. (2011). Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. Curr Med Res Opin 27(6): 1089–1096.
   PubMed Web of Science ®Google Scholar
• Souery, D., J. Amsterdam, C. de Montigny, Y. Lecrubier, S. Montgomery, O. Lipp, et al. (1999). Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol 9(1-2): 83–91.
   PubMed Web of Science ®Google Scholar
• Souery, D., P. Oswald, I. Massat, U. Bailer, J. Bollen, K. Demyttenaere, et al. (2007). Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68(7): 1062–1070.
   PubMed Web of Science ®Google Scholar
• Souery, D., A. Serretti, R. Calati, P. Oswald, I. Massat, A. Konstantinidis, et al. (2011). Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol 31(4): 512–516.
   PubMed Web of Science ®Google Scholar
• Souery, D., A. Serretti, R. Calati, P. Oswald, I. Massat, A. Konstantinidis, et al. (2011). ”Citalopram versus desipramine in treatment resistant depression: Effect of continuation or switching strategies. A randomized open study. World J Biol Psychiatry 12(5): 364–375.
   PubMed Web of Science ®Google Scholar
• Stahl, S. M., R. Entsuah and R. L. Rudolph (2002). Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression. Biol Psychiatry 52(12): 1166–1174.
   PubMed Web of Science ®Google Scholar
• Stamouli, S. S., A. Yfantis, E. Lamboussis, A. Liakouras, V. Lagari, M. Tzanakaki, et al. (2009). Escitalopram in clinical practice in Greece: treatment response and tolerability in depressed patients. Expert Opin Pharmacother 10(6): 937–945.
   PubMed Web of Science ®Google Scholar
• Thase, M. E. (2001). The need for clinically relevant research on treatment-resistant depression. J Clin Psychiatry 62(4): 221–224.
   PubMed Web of Science ®Google Scholar
• Wade, A. G., G. M. Crawford and A. Yellowlees (2011). Efficacy, safety and tolerability of escitalopram in doses up to 50 mg in Major Depressive Disorder (MDD): an open-label, pilot study. BMC Psychiatry 11: 42.
   PubMed Web of Science ®Google Scholar
• Zhong, H., N. Haddjeri and C. Sanchez (2012). Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter a review of current understanding of its mechanism of action. Psychopharmacology (Berl) 219(1): 1–13.
   PubMed Web of Science ®Google Scholar